Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronnie Neuberg

Pediatrics West Columbia, SC Medical Doctor

NPI 1457328932 CMS profile 974118

112 Saluda Ridge Ct Ste 200, West Columbia, SC 29169

Open in the dashboard

General payments

$454

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronnie Neuberg of West Columbia, SC is reported in the CMS Open Payments database as having received $454 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2023 General $14 1
2022 General $70 3
2021 General $139 7
2020 General $150 3
2019 General $65 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronnie Neuberg
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Ronnie Neuberg were reported at $15. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Ronnie Neuberg Pediatrics median Middle half National median
2019 $65 $86 $31–$183 $163
2020 $150 $49 $22–$110 $114
2021 $139 $68 $27–$158 $132
2022 $70 $77 $30–$173 $149
2023 $14 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $15 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Horizon Therapeutics plc $197 5 payments
  2. AbbVie, Inc. $48 2 payments
  3. CSL Behring $38 1 payment
  4. Biogen, Inc. $27 1 payment
  5. Janssen Biotech, Inc. $21 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $19 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $18 1 payment
  8. UCB, Inc. $18 1 payment
  9. Sandoz Inc. $15 1 payment
  10. Argenx US, Inc. $14 1 payment
  11. Other $37 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $454 18 payments
Products named General payments · program years 2019–2025
  1. KRYSTEXXA $156 3 payments
  2. SKYRIZI $48 2 payments
  3. TEPEZZA $41 2 payments
  4. Hizentra $38 1 payment
  5. ADUHELM $27 1 payment
  6. STELARA $21 1 payment
  7. TRINTELLIX $19 1 payment
  8. SYNJARDY $18 1 payment
  9. JARDIANCE $18 1 payment
  10. Cimzia $18 1 payment
  11. Other $79 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$7,019,586

Of which drugs: $6,931,501

Medicare patients

740

Average age 74

Services billed

576,261

573 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Osteoporosis 60%
Arthritis 53%
Ischemic heart disease 29%
Diabetes 24%
Depression 24%
Chronic kidney disease 22%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 363 31,320 $624,868
Injection, tildrakizumab, 1 mg J3245 Office 15 5,200 $559,279
Injection, vedolizumab, 1 mg J3380 Office 20 30,900 $538,488
Injection, ocrelizumab, 1 mg J2350 Office 16 12,000 $503,503
Injection, belatacept, 1 mg J0485 Office 27 116,500 $339,656
Injection, omalizumab, 5 mg J2357 Office 14 9,615 $266,933
Injection, romosozumab-aqqg, 1 mg J3111 Office 28 21,840 $184,419
Injection, lecanemab-irmb, 1 mg J0174 Office 25 166,230 $174,093
Injection, inclisiran, 1 mg J1306 Office 41 17,040 $161,171
Injection, eptinezumab-jjmr, 1 mg J3032 Office 23 11,600 $147,001

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record